HK1198947A1 - Thromboembolism preventive/therapeutic agent for thromboembolism patients having severe renal dysfunction - Google Patents
Thromboembolism preventive/therapeutic agent for thromboembolism patients having severe renal dysfunction Download PDFInfo
- Publication number
- HK1198947A1 HK1198947A1 HK14112667.1A HK14112667A HK1198947A1 HK 1198947 A1 HK1198947 A1 HK 1198947A1 HK 14112667 A HK14112667 A HK 14112667A HK 1198947 A1 HK1198947 A1 HK 1198947A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- thromboembolism
- edoxaban
- preventive
- therapeutic agent
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011273516 | 2011-12-14 | ||
| JP2011-273516 | 2011-12-14 | ||
| PCT/JP2012/082279 WO2013089164A1 (fr) | 2011-12-14 | 2012-12-13 | Agent préventif/thérapeutique d'une thromboembolie destiné à des patients souffrant d'une thromboembolie et présentant un dysfonctionnement rénal sévère |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1198947A1 true HK1198947A1 (en) | 2015-06-19 |
Family
ID=48610739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112667.1A HK1198947A1 (en) | 2011-12-14 | 2012-12-13 | Thromboembolism preventive/therapeutic agent for thromboembolism patients having severe renal dysfunction |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20130158069A1 (fr) |
| EP (1) | EP2792357A4 (fr) |
| JP (1) | JPWO2013089164A1 (fr) |
| KR (1) | KR20140102675A (fr) |
| CN (1) | CN103987389A (fr) |
| HK (1) | HK1198947A1 (fr) |
| TW (1) | TW201330852A (fr) |
| WO (1) | WO2013089164A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597109A (en) | 2007-03-29 | 2013-01-25 | Daiichi Sankyo Co Ltd | Tablet composition having favorable dissolution property useful as an anticoagulant |
| JP5652879B2 (ja) | 2009-03-13 | 2015-01-14 | 第一三共株式会社 | 光学活性なジアミン誘導体の製造方法 |
| JP2017509622A (ja) * | 2014-03-31 | 2017-04-06 | 第一三共株式会社 | 抗凝固薬として使用されるビタミンＫ拮抗薬に感受性を有する患者における、出血事象及び関連障害を治療及び予防するための第Ｘａ因子阻害薬の使用 |
| US20170231969A1 (en) * | 2014-08-06 | 2017-08-17 | Sandoz Ag | Pharmaceutical Compositions of Edoxaban |
| US20170368037A1 (en) * | 2014-12-26 | 2017-12-28 | Daiichi Sankyo Company, Limited | Pharmaceutical composition for promotion of fibrinolysis |
| KR102222774B1 (ko) * | 2018-07-27 | 2021-03-04 | 보령제약 주식회사 | 에독사반을 포함하는 약학적 제제 및 이의 제조방법 |
| CN112107551A (zh) * | 2019-06-19 | 2020-12-22 | 北京万全德众医药生物技术有限公司 | 一种依度沙班冻干口崩片及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003000657A1 (fr) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Derives de diamine |
| DK1405852T3 (da) | 2001-06-20 | 2012-08-27 | Daiichi Sankyo Co Ltd | Diaminderivater |
| EP2374456B1 (fr) * | 2008-12-19 | 2016-08-03 | Daiichi Sankyo Company, Limited | Posologie d'edoxabane |
-
2012
- 2012-07-20 US US13/554,610 patent/US20130158069A1/en not_active Abandoned
- 2012-12-12 TW TW101146787A patent/TW201330852A/zh unknown
- 2012-12-13 CN CN201280061665.2A patent/CN103987389A/zh active Pending
- 2012-12-13 KR KR1020147015787A patent/KR20140102675A/ko not_active Withdrawn
- 2012-12-13 EP EP12857962.0A patent/EP2792357A4/fr not_active Withdrawn
- 2012-12-13 JP JP2013549301A patent/JPWO2013089164A1/ja active Pending
- 2012-12-13 HK HK14112667.1A patent/HK1198947A1/en unknown
- 2012-12-13 WO PCT/JP2012/082279 patent/WO2013089164A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2792357A4 (fr) | 2015-05-20 |
| JPWO2013089164A1 (ja) | 2015-04-27 |
| EP2792357A1 (fr) | 2014-10-22 |
| WO2013089164A1 (fr) | 2013-06-20 |
| KR20140102675A (ko) | 2014-08-22 |
| CN103987389A (zh) | 2014-08-13 |
| US20130158069A1 (en) | 2013-06-20 |
| TW201330852A (zh) | 2013-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Summer et al. | Activation of the mTORC1/PGC-1 axis promotes mitochondrial biogenesis and induces cellular senescence in the lung epithelium | |
| HK1198947A1 (en) | Thromboembolism preventive/therapeutic agent for thromboembolism patients having severe renal dysfunction | |
| US8962574B2 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy | |
| KR20140056212A (ko) | 골수성증식 신생물과 같은 암 치료에서의 파노비노스타트와 룩소리티닙의 조합물 | |
| JP6283766B2 (ja) | 血液障害の処置に使用するためのｇｌｙｔ１阻害剤 | |
| KR20170122777A (ko) | 트라디피턴트에 의한 치료 방법 | |
| JP2023175694A (ja) | ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドの組成物 | |
| CA2770698C (fr) | Utilisation de 4-aminopyridine pour ameliorer un dysfonctionnement neurocognitif et/ou neuropsychiatrique dans des patients atteints d'etats demyelinisant et d'autres etats du systeme nerveux | |
| CN115003297A (zh) | 使用伐达度司他的治疗方法 | |
| EP4335516A2 (fr) | Acylsulfonamides à titre d'antagonistes de la famille bcl destinés à être utilisés dans la gestion clinique d'états pathologiques provoqués ou induits par des cellules sénescentes ainsi que dans le traitement du cancer | |
| Amiri et al. | Drug-induced Tongue Disorders: A Comprehensive Literature Review | |
| EP2766017B1 (fr) | Procédés de traitement d'une déficience sensorimotrice liée à un accident vasculaire cérébral à l'aide d'aminopyridines | |
| US20230026808A1 (en) | Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury | |
| US20110251160A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| US20070259913A1 (en) | Prophylaxis of thromboembolic events in cancer patients | |
| US20140100244A1 (en) | Preventive And/Or Therapeutic Agent For Thromboembolism In Thromboembolism Patient With Severe Renal Impairment | |
| US20140371262A1 (en) | Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment | |
| JP2018521077A (ja) | 糖尿病性腎症を治療するためのｐｄｅ４阻害剤 | |
| AU2019200876B2 (en) | Panobinostat dosages for multiple myeloma | |
| Yong et al. | Synergism in pharmacokinetics of retagliptin and metformin observed during clinical trials of their combination therapy | |
| WO2024211216A1 (fr) | Cilnidipine et inhibiteur de p-glycoprotéine pour le traitement de la douleur | |
| US20180243247A1 (en) | Drug combinations for cerebrovascular disease | |
| JP2006104198A (ja) | 消炎鎮痛薬及びアレルギー疾患治療薬 | |
| EP3243516A1 (fr) | Procédés permettant de traiter des troubles sensori-moteurs associés à certains types d'accidents vasculaires cérébraux à l'aide d'aminopyridines | |
| Abais | Redox Triggering of Podocyte NLRP3 Inflammasomes and Glomerular Injury in Hyperhomocysteinemia |